PMD-026
As of the edition of 20 October 2026, PMD-026 is a drug known only by a code name: in active development; acts on RPS6KA1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Code name only
- Registered trials
- 2, 0 stopped early
- Disease areas
- Cancer; Blood and lymph; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| RPS6KA1 | Ribosomal protein S6 kinase alpha-1 | Q15418 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 1 | 0 |
| Phase 2 | 1 | 0 | 1 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Phoenix Molecular Designs | Lead sponsor of trials | 2019 to now |